Perspectives in Cancer Prevention: A look into the Future
February 5-6, 2024
Agora, the Cancer Center Forum, Lausanne
Monday, February 5, 2024
8:30 – 9:00: Registration and Welcome Coffee
9:00 – 9:15: Cathrin Brisken: Welcome Address & Introduction to the CANCERPREV ITN Consortium
EPFL, Lausanne, Switzerland; ICR, London, UK
9:15-10:00: David Fisher: Pathways from molecular to behavioral that mediate melanoma risk
Lancer Professor of Dermatology, Massachusetts General Hospital, HMS, USA
Session 1: Global Issues/target populations
10:00 – 10:30: Irene Leigh: Keratinocyte cancers in the UK
Barts Centre for Squamous Cancer, Faculty of Medicine and Dentistry, QMUL, UK
10:30-11:00: Coffee break
11:00 – 11:30: Anguraj Sadanandam: Genomics and global health ware
Institute of Cancer Research (ICR), London, UK
11:30-12:00: Andrew Reynolds: Drug development for cancer prevention: opportunities and challenges
AstraZeneca, Cambridge, UK
12:00-12:30: Simona Cristea: Computational and machine learning models for breast cancer prevention
Harvard School of Public Health; Dana-Farber Cancer Institute, Boston, USA
12:30-14:00: ITN private lunch
Session 2: Genetic and environmental control of tumor susceptibility
14:00-14:30: Phil Jones: Genomics and somatic mutations in normal tissues
Wellcome Sanger Institute, Hinxton, UK
14:30-15:00: Tatiana Petrova: Organ-/cancer-specific vasculature
Unil, Lausanne, Switzerland
15:00-15:20: Short talk: Panagiota Tsokkou: Does Chronic Inflammation in Psoriasis affect Skin Cancer development?
Medical University of Vienna, Austria
15:20-15:40: Erwin Wagner & Latifa Bakiri: Inflammatory diseases and beyond
Medical University of Vienna, Austria
15:40-16:20 Coffee Break
16:20-16:50: Valerie Weaver
University of California, San Francisco, USA
16:50-17:10: Short talk: Emir Sehovic: Analysis of Circulating Biomarkers for Minimally Invasive Early Detection of Breast Cancer
Fondazione Edo ed Elvo Tempia, Biella, Italy
17:10-17:40: Sabine Werner: Stromal-epithelial cross-talk in wound healing and cancer
ETH Zurich, Switzerland
Tuesday, February 6th 2024
Session 3: Nuclear Hormone Receptor at the surface between the environment and the organism
9:00-10:00: ITN business meeting
10:00 – 10:30: Muriel Le Romancer: How PRMTs impact steroid receptor activity in breast cancer: from basic science to clinical perspectives
Centre de Recherche en Cancérologie de Lyon, France
10:30-11:00: Coffee break
11:00-11:30: Wouter Karthaus: Targeting lineage plasticity in prostate cancer
Assistant Professor Tenure Track, EPFL-ISREC, Lausanne, Switzerland
11:30-12:00: Gian-Paolo Dotto: Dual role of androgen receptor in skin cancer
University of Lausanne/CHUV, Switzerland; Massachusetts General Hospital, Harvard Medical School, Boston, USA
12:00-12:20: Short talk: Eirini Chrysanthou: Discovery and validation of sex-specific survival biomarkers in early-stage melanoma
Fondazione Edo ed Elvo Tempia, Biella, Italy
12:20-13:30: Lunch break
13:30-14:00: Speed talks for students presenting posters
14:00-15:00: Poster session
15:00-15:20: Short talk: Carlos Ronchi: EMBER creates a unified space for independent breast cancer transcriptomic datasets enabling precision oncology
EPFL, Lausanne, Switzerland
15:20-15:40: Emmy Verschuren: Issues related to translation
University of Helsinki, Finland
15:20-16:10: Victor Corces: Bisphenol A, chromatin modifications x environmental influences
Emory University School of Medicine, Atlanta, US
16:10-16:40: Coffee break
Final Session: Roundtable discussion – The future of Cancer Prevention
16:40-17:40: Led by: John Hickman (Consilium Scientific, London, UK)
Andrew Reynolds: Senior Director, Oncology R&D, AstraZeneca
Cathrin Brisken: EPFL, Lausanne, Switzerland; ICR, London, UK
Emmy Verschuren: University of Helsinki, Finland
Irene Leigh: Barts Centre for Squamous Cancer, Faculty of Medicine and Dentistry, Queen Mary University of London
17:45-18:00: Closing remarks/event wrap-up